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to evaluate mean annual total health care cost per-capita and mortality. RESULTS:
The annual rate of first ICD implant (per million-persons) increased, from 55 in 2000
to 236 by 2008. The use of ICD in Lombardy was approximately 2 times higher than
in Europe and 3-4 times lower than in US. The replacement rate was around 10 (per
hundred implant-year) with a peak in 2005. The hospitalization for a first ICD
implant cost €23,814 (CI95%, 23,676-23,960) on average. During follow-up, 15.4% of
patients died and the HS bore a mean annual cost of €4,354 (CI95% 4,226-4,485)
per-capita: 17% due to drugs, 12% to outpatient visits and 71% to hospitalizations.
Younger patients reported lower costs in drug treatments and outpatient visits and
a higher expenditure for hospitalizations. CONCLUSIONS: ICD use is growing and
it’s important to assess the efficacy and the burden of this therapy, given the
economic implications and differences in use among countries. Health care admin-
istrative databases are a useful tool, as they provide information about large unse-
lected populations.
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OBJECTIVES: International best-practice guidelines for self-monitoring of blood
glucose recommend testing for patients on basal insulin be limited to twice daily,
with periodic testing for patients on oral glucose lowering therapies including in-
sulin secretagogues and insulin sensitisers. The aim of this study is to estimate the
potential cost savings if frequency of self-monitoring of blood glucose in patients
with Type 2 diabetes in Ireland is rationalised according to these guidelines.
METHODS:Data were analysed using 1) a national prescription claims database for
2011 (dispensed data), and 2) a survey conducted on 604 Type 2 diabetes patients in
2011 (self-reported data). Patients receiving prescriptions for diabetes were identi-
fied and total ingredient cost and quantity of test strips dispensed were calculated.
Drugs and diagnostic test strips were classified and identified according to the
WHO ATC classification system. Frequency of testing for various treatment strat-
egies was obtained. Analysis was performed in SAS (v9.1) RESULTS: The total in-
gredient cost of test strips was €24.5m (dispensed data) and €118,625.47 (self-re-
ported data) in 2011. The average frequency of testing for patients on oral agents
was 3 times daily (both insulin secretagogues and sensitisers) (dispensed data)
compared to once daily (self-reported data). CONCLUSIONS: Results from this
study indicate cost savings of approximately €10.4m per annum should frequency
of blood glucose monitoring be restricted to patients on insulin containing regi-
mens alone. The results also highlight a difference in frequency of blood glucose
monitoring between dispensed data and self-reported data, indicating the wastage
that currently exists in the system.
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OBJECTIVES: Model cost-effectiveness of home Telemonitoring (TM) or Structured
Telephone Support (STS) strategies versus usual care for adults recently discharged
(within 28 days) after a Heart Failure (HF) exacerbation in Engalnd and Wales.
METHODS: A Markov model evaluated 4 interventions: a) STS Human to Machine,
b) STS Human to Human, and c) TM during office hours d) usual care. Given heter-
ogeneity in the interventions, cost-effectiveness analysis was performed using
bottom up costing scenarios regarding costs of devices, monitoring and medical
care to deal with alerts. Costs and QALYs over a 30 year horizon depend on monthly
probability of death and monthly risks of hospitalisations (HF-related complica-
tions or other causes) computed using a Bayesian network meta-analysis of inter-
vention trials. RESULTS: Base case monthly costs per patient were: £27 for usual
care, £119 for STS HM, £179 for STS HH and £175 for TM during office hours. The
base case found that TM during office hours was the most cost-effective strategy.
Compared with usual care, TM during office hours had an estimated incremental
cost effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an ICER of
£63,240/QALY against TM during office hours. STS HM was dominated by usual
care. PSA showed probabliities of cost-effective for TM during office hours cost
effective of 44%, STS HH 36%, STS HM 18% and usual care 2%. Threshold analysis
suggested that the monthly cost of TM during office hours has to be higher than
£390 to have an ICER greater than £20,000/QALY against STS HH. Scenario analyses
performed using higher costs of usual care, higher costs of STS HH and lower costs
of TM during office hours do not substantially change the conclusions.
CONCLUSIONS:Cost-effectiveness analyses suggest TM during office hours was an
optimal strategy in most scenarios, but there is considerable uncertainty in relation
to clear descriptions of the interventions and robust estimation of costs.
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OBJECTIVES: The health care sector in India is growing rapidly while facing in-
creased demands for quality and efficiency of care. We have developed an agent-
based model (ABM) of cardiovascular disease (CVD) for India to inform relevant
health care policy and investment decisions by simulating infrastructure expan-
sion scenarios and estimating associated health care requirements and health and
economic impacts. METHODS: The primary agents in our model are individual
health care facilities, including hospitals and health care centers. Health care fa-
cilities are configured by model users and placed in selected jurisdictions to simu-
late multiple CVD diagnostic and treatment strategies over a time horizon of up to
20 years. A facility description includes basic patient information, the catchment
population served by the facility, the diagnostic capacity of that facility (e.g., how
many ECG tests the facility can provide), and the diagnostic strategies used by that
facility to diagnose CVD. Multiple sets of patient-strategy combinations can be
defined for each facility allowing for inter-facility and intra-facility comparisons.
Using this information, each facility in the CVD model calculates a total patient
population, segments the patient population into individual patient groups, and
runs these groups through specified diagnostic strategies. Our CVD ABM was de-
veloped using the Repast Simphony ABM environment. RESULTS: The results of
running each patient group through the specified strategies are recorded and used
to calculate multiple health and economic summary metrics. The metrics include
diagnostic outcomes, costs, quality-adjusted life years, capacity metrics, and a
customized composite score. The results of an example scenario will be reported.
CONCLUSIONS: CVD ABM has potential to inform complex health care infrastruc-
ture investment decisions that could improve access to CVD care and positively
affect health and economic outcomes, while increasing operational efficiency of
health care delivery in India.
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OBJECTIVES: In Japan, cancer screening is not covered by health insurance, but is
provided and paid for by local governments. In clinical practice, asymptomatic
subjects have undergone upper gastrointestinal endoscopy as cancer screening
that has been charged to health insurance. In order to file a claim for health insur-
ance, the actual name of the disease must be reported even for an asymptomatic
person. The number of upper gastrointestinal endoscopic examinations for asymp-
tomatic persons in clinical practices was estimated based on the national health
insurance data and the national patients’ survey. METHODS: There were 501,002
endoscopic examinations and 178,200 persons with gastric diseases in 2008. The
appropriate numbers of endoscopic examinations were calculated based on the
following models. At admission, an endoscopic examination was performed once
for each patient. For outpatient cases at the first visit, an endoscopic examination
was performed once for gastric and esophageal cancer patients and 0.5 times for
patients with another upper gastrointestinal disease. For outpatient follow-up,
patents were examined once a year if they had a gastric cancer or an esophageal
cancer and 0.5 times a year if they had another upper gastrointestinal disease. A
sensitivity analysis of the number of endoscopic examination of outpatients with
another upper gastrointestinal disease was performed by changing the number of
examinations from 0.1 to 0.8 times for outpatients both at the first visit and at
follow-up. The difference between the estimated and observed numbers was de-
fined as representing the number of inappropriate endoscopic examination per-
formed for asymptomatic patients. RESULTS: Using the initial assumptions,
asymptomatic patients accounted for 30.8% of all cases undergoing upper endos-
copy. On sensitivity analysis, this ranged from 2.2% to 69.0%. CONCLUSIONS: The
results suggest that a substantial number of upper gastrointestinal endoscopies are
performed for asymptomatic patients in clinical practice, and this cannot be ig-
nored.
PMD88
DISPARITIES IN ACCESS TO EGFR-MUTATION TESTING IN PATIENTS WITH
ADVANCED NSCLC IN GERMANY 2011
Kellermann L1, Ukena D2
1OncologyInformationService, Freiburg, Germany, 2Klinikum Bremen-Ost GmbH, Bremen,
Germany
OBJECTIVES: The data from clinical trials show, that in patients with advanced
non-small-cell lung-cancer and with activating EGFR-mutations first-line use of
tyrosine kinase inhibitors (TKI) may be of advantage compared to standard doublet
chemotherapy. However, testing of all newly diagnosed patients with advanced
NSCLC has been considered as a financial burden in daily clinical routine. The rate
of EGFR-testing in daily practice was analyzed by institution type, histology, indi-
vidual patient characteristics and by federal state. The EGFR-test processing was
analyzed with respect to sampling, quality of samples, referral to the certified
pathologists, reimbursement and coverage of costs. METHODS: The online survey
was performed in a representative sample of decision making physicians in 102
centres (21 university hospitals, 44 non-university hospitals, 32 office-based oncol-
ogists, 5 lung clinics) treating patients with advanced NSCLC in the 3rd quarter of
2011. The impact of relevant factors (turn-around time, regional density of hospi-
tals or specialist physicians, the type of test-initiating institution) on the likelihood
of testing was assessed by using a two-sided Chi-square test RESULTS: Only a
minority of patients with NSCLC IIIb/IV (40%) had access to EGFR-testing and to the
respective treatment in case of a mutation in Q3 2011. Reasons may include the
long waiting-time for test results (mean 9.2 d, range 5-14 d), the inadequate reim-
bursement of testing, esp. in lung clinics, and patient selection according to indi-
vidual characteristics by the physician in order to reduce the test rates and the
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burden for clinical budgets. The regional data analysis indicates that patient access
to EGFR-mutation testing is significantly related to the density of clinics and of
specialized physicians in respective federal states. CONCLUSIONS: Decentralized
organization and funding of health care and diagnostics have led to significant
regional disparities. Therefore, a detailed analysis of regional health care struc-
tures in oncology is necessary.
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OBJECTIVES: Current practice for suspected acute coronary syndrome (ACS) in-
volves troponin testing 10-12 hours after symptom onset to diagnose myocardial
infarction (MI). We aimed to estimate the diagnostic accuracy of early biomarkers
for MI to determine if an earlier, accurate decision was possible. METHODS: A
systematic review of all diagnostic cohort studies of patients presenting with sus-
pected ACS comparing the following biomarkers at presentation with a reference
standard based on the Universal definition of MI (troponin at 10-12 hours): early
troponin I and T; Heart-type Fatty Acid Binding Protein (HFABP); ischaemia modi-
fied albumen (IMA) and myoglobin. A systematic search was undertaken of 10
electronic databases, citation lists and expert contacts, to identify relevant studies.
The study selection, data extraction and quality assessment decisions were all
verified by more than one reviewer. citations retrieved were divided between two
reviewers (CC, SG) and screened for relevance to the review. Any discrepancies
were resolved by discussion and reference to the full paper. Risk of bias was as-
sessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
tool. Meta-analysis was conducted using Bayesian Markov chain Monte Carlo
simulation. RESULTS: Compared with the Universal definition of MI, sensitivity
and specificity (95% predictive interval) were 77% (29-96%) and 93% (46-100%) for
troponin I; 80% (33-97%) and 91% (53-99%) for troponin T (99th percentile thresh-
old); 81% (50-95%) and 80% (26-98%) for quantitative HFABP, 68% (11-97%) and 92%
(20-100%) for qualitative HFABP; 77% (19-98%) and 39% (2-95%) for IMA and 62%
(35-83%) and 83% (35-98%) for myoglobin. CONCLUSIONS: Early troponin I and T
and H-FABP have modest sensitivity and specificity for MI at presentation, when
compared with the gold standard, but estimates are subject to substantial uncer-
tainty and primary data are subject to substantial heterogeneity. More research on
high sensitivity troponin assays at presentation is required.
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OBJECTIVES: The regional Committee for Medical Devices Evaluation drafted the
HTA report for decision making on denervation of renal artery by catheter-based
radioablation in the treatment of resistant hypertension. METHODS: The report
was implemented in the respect of the INAHTA checklist form and its next versions
(WP4-EUnetHTA Project). Major literature and institutional databases were
searched (November 2011). A budget impact analysis (3-year horizon) in the re-
gional perspective was implemented on patients (aged 35-75) affected by resistant
hypertension (diastolic blood pressure 140mm/Hg) on politherapy treatment
(four antihypertensive drugs, including a diuretic). The target population excluded
secondary hypertension and included subjects actually hypertensive, treated, and
resistant to therapies, affected by comorbidities. The model was populated by
literature data as to epidemiology, resources consumption of denervation proce-
dure and cost/patient/year of antihypertensive therapy (visits, drugs, comorbidi-
ties management). Units costs were derived from a hospital accounting office (2010
values). RESULTS:No guidelines mentioned radiofrequency energy device as alter-
native to antihypertensives. Published clinical data, even limited, reveal an encour-
aging security profile. Two trials assessed blood pressure reduction in treated pa-
tients, at 2 years and 6 months. Seven clinical trial were found as on going. No
report of HTA or cost evaluation are published.The model target population con-
sisted of 8.559 subjects. Procedure costs, including overheads costs, was estimated
to be about €7,000; usual antihypertensive treatment about €600/patient/year. The
introduction of the device in clinical practice (hypothesis: 2% at 3rd year) would
increase regional expenditure in the range of 5%- 22%, respectively at 1st and 3rd
year from implementation. The model was sensitive to antihypertensives cost and
number of eligible patients. On the basis of clinical evidences, a one-year controlled
introduction of procedure was decided. CONCLUSIONS: Renal denervation is a
potential alternative in the treatment of patients affected by resistant hyperten-
sion.
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OBJECTIVES:A lot of uncertainties exist when introducing new technologies to the
health care market. The objective of this study is to construct different implemen-
tation scenarios of Home Brain Monitoring (HBM) in epilepsy patients and to value
these scenarios by making use of real options modeling to address uncertainty.
This model tries to show the (financial) consequences of different uncertainties on
the total value of the HBM project to facilitate investment decisions in the future.
METHODS: Individual semi-structured interviews were used to present (imple-
mentation) uncertainties to 19 epilepsy experts. Expert elicitation was used to
collect beliefs regarding uncertainties of HBM and to estimate probabilities of ‘suc-
cess’ of uncertainties. Scenarios were constructed, each of which describe a set of
uncertainties. These uncertainties were resolved in order to obtain a production
process with a certain expected value. Finally, a real options model was developed
that shows the influence of uncertainties on the total value of the HBM project.
Sensitivity analysis was used to demonstrate the impact of different uncertainties.
RESULTS: Elicited judgments show that a promising implementation scenario of
HBM in the diagnostic track of epilepsy could be the implementation of HBM after
a negative routine EEG, as a substitution of subsequent recordings and with the
support of a detection algorithm to detect events automatically. The probability of
success was lowest for implementing HBM without making use of a detection
algorithm. However, implementing HBM before the first EEG recording yields the
highest value, but it is not likely to happen.CONCLUSIONS: The implementation of
HBM after routine EEG seems to be preferred. The real options model provides an
innovative way to represent and value uncertainty in R&D projects. This model is
used for the first time in health care technology and provides a comprehensive, but
not-too-detailed view of challenges and key criteria for success.
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OBJECTIVES: A range of inhaler devices is available for the delivery of treatments
for respiratory diseases (pressurized metered-dose inhalers [pMDIs], non-refillable
and refillable dry-powder inhalers [DPIs], and breath-actuated metered-dose inhal-
ers [BA-MDIs]). Sales data from retail pharmacies in the five largest European coun-
tries for the period from Q4 2005 to Q4 2011 were analysed as a measure of inhaler
use in respiratory disease therapy. METHODS: Sales data were obtained from the
MIDAS database (IMS Health, London, UK) for CFC-free pMDIs, DPIs (non-refillable
and refillable) and BA-MDIs. Retail unit (RU) sales were analysed on a quarterly
basis, with one RU equating to one pack of inhalers. RESULTS: pMDIs accounted for
more than 50% of the total inhalers used across the four device types in every
quarter analysed. At the beginning of the study period, pMDIs accounted for 58.0%
of inhalers used, with non-refillable DPIs, refillable DPIs and BA-MDIs accounting
for 25.2%, 12.5% and 4.3%, respectively. At the end of the study period, the corre-
sponding percentages were 55.6% for pMDIs, 25.8% for non-refillable DPIs, 15.3% for
refillable DPIs and 3.3% for BA-MDIs. For each quarter, the number of pMDI RUs sold
was approximately twice that of non-refillable DPIs and three times that of refill-
able DPIs. The highest total number of RUs (45.7 million) was recorded in the most
recent quarter analysed; pMDIs accounted for 25.4 million RUs, compared with 11.8
million for non-refillable DPIs, 7.0 million for refillable DPIs and 1.48 million
BA-MDIs. CONCLUSIONS: These retail pharmacy data suggest that pMDIs are the
most commonly used inhaler for the treatment of respiratory disease in the five
largest EU countries. The trends observed in this analysis may reflect physician
consideration of factors such as the real-world effectiveness of, and the overall
health care costs associated with, the different inhaler types.
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OBJECTIVES: Early evaluations of new technologies require knowledge about cur-
rent care. Guidelines are sometimes used as a proxy. We examined the degree of
compliance to guidelines for the care of patients with a recent TIA or minor isch-
emic stroke. We specifically focussed on the guidelines for carotid stenosis imaging
and treatment criteria. METHODS: Semi-structured interviews are being con-
ducted with neurologists and radiologists in 13 hospitals in different regions in the
Netherlands. Questions were asked about the use of initial and confirmatory non-
invasive imaging tests to assess carotid stenosis (emergency and outpatient clinic),
criteria used to perform confirmatory tests and treatment criteria. We also exam-
ined the causes of variation and reasons for deviating from the guidelines.
RESULTS:To date, we have conducted interviews with specialists at nine hospitals.
The Dutch guidelines recommend duplex ultrasonography (DUS) as initial test. If
carotid stenosis is70% for females or 50-69% for males, a confirmatory computed
tomography angiography (CTA) or magnetic resonance angiography is advised. We
observed that only four of nine hospitals actually follow these guidelines in current
practice; the other hospitals use differing test combinations (e.g. CTA only with no
confirmatory test; or two DUS tests, followed by confirmatory CTA if DUS results
differ). According to clinicians, these differences are caused by varying expertise in
performing tests, capacity problems and preferences of vascular surgeons. We
observed little variation in treatment criteria, with good correspondence to the
guidelines. CONCLUSIONS: If guidelines are not followed, then early economic
evaluations using guidelines as the basis to describe current care may lead to
incorrect conclusions about the cost-effectiveness of a new technology. Moreover,
important practice variation means that the use of just one comparator is unjus-
tified. Assessments of health and economic impact of new imaging technology will
therefore be hospital-dependent and require multiple comparisons and scenarios.
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